Transgene: A positive 2018, moving ahead with a strong portfolio

Transgene: A positive 2018, moving ahead
with a strong portfolio

* Clinical trials set to announce key data in 2019
* Invir.IO(TM) platform designed to deliver a new generation of oncolytic viruses has demonstrated promising preclinical data and is progressing to clinical stage
* Launch of myvacTM - our platform for highly innovative virus-based, individualized immunotherapy has already achieved multiple milestones translated into a strategic partnership with NEC
* Received $48 million in Tasly Biopharmaceuticals Co., Ltd. ('Tasly') shares through the sale of TG1050 and TG6002 rights to Tasly in Greater China
* Key financial elements:
- €8 million in net income in 2018 as a result of the Tasly deal
- €20 million revolving credit facility secured, using its Tasly shares as collateral
- Financial visibility extended until mid-2020

Conference call scheduled today at 6:30 p.m. CET (in English) (details at the end of this release)